Babraham Bioscience Technologies' Technology Development Laboratory moves to Abzena


Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into an agreement with Babraham Bioscience Technologies Limited, (BBT) the company that manages and develops the Babraham Research Campus, to run and develop the services formerly provided by BBT’s Technology Development Laboratory (TDL).

This agreement allows a seamless transition of current projects, together with the capabilities, resources and expertise from the TDL to Abzena. These capabilities include enzymatic assay development, small molecule inhibitor screening, molecular biology, cell culture and protein purification. These capabilities will complement and integrate into Abzena’s existing broad range of solutions, including antibody engineering, bioassay and bioanalytical services and cell line development to enable the progress of biopharmaceutical research from discovery through to manufacturing for clinical trials.

Abzena will also expand on TDL’s current antibody discovery capabilities to offers its clients a platform for the rapid generation of hybridoma cell lines expressing high affinity antibodies to their chosen target.

Campbell Bunce, SVP Scientific Operations, Abzena said: “Bringing the expertise of the TDL scientists into Abzena and integrating them into our offering across biology and biomanufacturing aligns very well with our services and technologies as a solution provider for drug developers and augments the overall toolbox we can offer our customers. We look forward to building on the knowledge that the TDL team has brought and continuing an excellent working relationship with their current partners.”

Derek Jones, CEO, Babraham Bioscience Technologies said: “We have had a long tradition in supplying this expertise from the TDL, but have experienced challenges in scaling up the services to provide an end-to-end solution to our customer base. We are pleased that these skills and expertise will be utilised and expanded by Abzena, particularly given that the capability will remain available at the Babraham Research Campus, as well as to the wider customer base.”

 About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term ‘ABZENA Inside’ is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ‘ABZENA Inside’ products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

  •     Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;
  •     Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
  •     Cell line development for the manufacture of recombinant proteins and antibodies;
  •     Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
  •     Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
  •     Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
  •     GMP manufacturer of ADC linkers, payloads & combined linker-payloads.

For more information, please see


Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

Babraham Research Campus Ltd.